PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 5 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 6 months ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
BRIEF published on 11/15/2024 at 13:05, 1 year 6 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 6 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 6 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
BRIEF published on 11/13/2024 at 00:28, 1 year 6 months ago Theralase Technologies prolonge l'expiration du mandat jusqu'en 2027 Bourse De Croissance TSX Traitement Du Cancer Technologies Théralase Développement Pharmaceutique Prolongation Du Mandat
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 6 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 7 months ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 1 year 7 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 7 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 05/16/2026 at 01:15, 16 hours 29 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 17 hours 44 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 18 hours 34 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 18 hours 44 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/16/2026 at 16:08, 1 hour 35 minutes ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 21 hours 34 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 23 hours 33 minutes ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 15:08, 1 day 2 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 1 day 2 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 1 day 7 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 2 days 8 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 2 days 23 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
